A Phase 1 interventional study of GSK2330672 (linerixibat) and Obeticholic acid in Cholestasis, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-24.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Cholestasis with a site in United Kingdom — 1 open to participants now, 3 under way, 1 of them phase 3. Cholestasis · United Kingdom.
Among the 17 studies in Cholestasis with a site in United Kingdom, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 1, and was the 10th registered.
150 studies on the registry are indexed under Cholestasis; 18 are open to participants now.
Browse Cholestasis studies →1 of the 17 studies in Cholestasis with a site in United Kingdom is open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–50 · Women only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 9 Cholestasis studies recruiting now, 1 sets no upper age limit and 8 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2019.
This study's enrollment of 19 is below the median of 53 across 90 interventional studies indexed under Cholestasis.
Median enrollment 62 across the 15 interventional studies, 140 across the 2 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 17 have an industry lead sponsor. The 8 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 6 studies filed under Cholestasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Cholestasis with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In participants with inadequate response/intolerance to ursodeoxycholic acid (UDCA) taking obeticholic acid (OCA) who experience pruritus (due to primary biliary cholangitis [PBC], OCA, or both) the addition of linerixibat to OCA therapy may be considered following marketing approval. It is therefore important to characterize any potential effect of linerixibat on the pharmacokinetics of OCA in humans at clinically relevant dosages. Accordingly, a drug-drug interaction (DDI) study with linerixibat (potential perpetrator) and OCA (potential victim) will be conducted to inform both future clinical trials with linerixibat and the potential concomitant administration of these drugs in a clinical setting. This is a single-center, one part (with optional second part) open-label, single sequence crossover, drug interaction study to investigate the effect of linerixibat on plasma concentrations of OCA and OCA conjugates in healthy participants. Approximately 19 participants will be enrolled in part A and further 19 participants in part B (if performed) in the study and will have a phone call follow-up till 7-14 days post-last linerixibat dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.
Drug: GSK2330672 (linerixibat) · Drug: Obeticholic acid
GSK2330672 is available as a tablet with unit dose strength of 45 mg.
Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Pharmacokinetic (PK) Parameters Population consisted of all participants for whom pharmacokinetic parameters were derivable.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Area Under the Concentration-time Curve From Time 0 to 24 Hour (AUC[0-24]) for Total-OCA at Steady State: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Maximum Observed Concentration (Cmax) for Total-OCA at Steady State: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Average Trough Concentration (Ctrough) for Total-OCA at Steady State: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Average Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- AUC(0-t) for Total-OCA at Steady State: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- AUC(0-24) for Total-OCA at Steady State: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Cmax for Total-OCA at Steady State: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Ctrough for Total-OCA at Steady State: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Tmax for Total-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 19) post-dose
Part A- Assessment of Steady State Using Ctrough of Total-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 hours and 24 hours (Day 38) post-dose
Part A- AUC(0-t) for OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- AUC(0-t) for OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- AUC(0-24) for OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- AUC(0-24) for OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Cmax for OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Cmax for OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Average Ctrough for OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Average Ctrough for OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Tmax for OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Tmax for OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- AUC(0-t) for Tauro-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- AUC(0-24) for Tauro-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Cmax for Tauro-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Cmax for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Average Ctrough for Tauro-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Average Ctrough for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Tmax for Tauro-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Tmax for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- AUC(0-t) for Glyco-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- AUC(0-24) for Glyco-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Cmax for Glyco-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Cmax for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Average Ctrough for Glyco-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Average Ctrough for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Tmax for Glyco-OCA: OCA Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part A- Tmax for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Tmax for Total-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Tmax for Total-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- AUC(0-t) for OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- AUC(0-t) for OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- AUC(0-24) for OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- AUC(0-24) for OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Cmax for OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Cmax for OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Ctrough for OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Ctrough for OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Tmax for OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Tmax for OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- AUC(0-t) for Tauro-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- AUC(0-24) for Tauro-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Cmax for Tauro-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Cmax for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Ctrough for Tauro-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Ctrough for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Tmax for Tauro-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Tmax for Tauro-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- AUC(0-t) for Glyco-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- AUC(0-24) for Glyco-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Cmax for Glyco-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Cmax for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Ctrough for Glyco-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Ctrough for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part B- Tmax for Glyco-OCA: OCA Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Day 17: Pre-dose; Day 18: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 19) post-dose
Part B- Tmax for Glyco-OCA: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
Time frame: Days 35 and 36: Pre-dose; Day 37: Pre-dose, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours (Day 38) post-dose
Part A- Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. All Participants Population consisted of all participants who took at least 1 dose of study intervention.
Time frame: Up to Day 52
Part B- Number of Participants With Any AEs and SAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement.
Time frame: Up to Day 52
Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QT Interval Corrected Using Bazzet's Formula (QTcB), Corrected QT Interval Using Fredericia's Formula (QTcF): OCA Arm
Twelve lead electrocardiograms (ECGs) were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1), and at Day 17
Part A- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF: OCA + Linerixibat Arm
Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1), and at Day 38
Part B- Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcB, QTcF
Twelve lead ECGs were planned to be measured PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were planned to be performed with the participant in a supine position after a rest of at least 5 minutes.
Time frame: Baseline (Day -1), and up to Day 38
Part A- Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): OCA Arm
SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1), Days 1 and 17
Part A- Change From Baseline in SBP and DBP: OCA + Linerixibat Arm
SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Pulse Rate: OCA Arm
Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1), Days 1 and 17
Part A- Change From Baseline in Pulse Rate: OCA + Linerixibat Arm
Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Respiratory Rate: OCA Arm
Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1), Days 1 and 17
Part A- Change From Baseline in Respiratory Rate: OCA + Linerixibat Arm
Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Body Temperature: OCA Arm
Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1), Days 1 and 17
Part A- Change From Baseline in Body Temperature: OCA + Linerixibat Arm
Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part B- Change From Baseline in SBP and DBP
SBP and DBP were planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Pulse Rate
Pulse rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Respiratory Rate
Respiratory rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Body Temperature
Body temperature was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.
Time frame: Baseline (Day -1), and up to Day 38
Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA Arm
Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes: OCA + Linerixibat Arm
Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA Arm
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA + Linerixibat Arm
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA Arm
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA + Linerixibat Arm
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA Arm
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA + Linerixibat Arm
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA Arm
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA + Linerixibat Arm
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA Arm
Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes: OCA + Linerixibat Arm
Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part B- Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, Leukocytes
Blood samples were planned to be collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Hematology Parameter: Hemoglobin
Blood samples were planned to be collected to analyze the hematology parameter: hemoglobin.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were planned to be collected to analyze the hematology parameter: hematocrit.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes
Blood samples were planned to be collected to analyze the hematology parameters: erythrocytes and reticulocytes.
Time frame: Baseline (Day -1), and up to Day 38
Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA Arm
Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea: OCA + Linerixibat Arm
Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA Arm
Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin: OCA + Linerixibat Arm
Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST): OCA Arm
Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Chemistry Parameters: ALT, ALP, AST: OCA + Linerixibat Arm
Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part A- Change From Baseline in Chemistry Parameter: Protein: OCA Arm
Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 17
Part A- Change From Baseline in Chemistry Parameter: Protein: OCA + Linerixibat Arm
Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and at Day 38
Part B- Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea
Blood samples were planned to be collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin
Blood samples were planned to be collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Chemistry Parameters: ALT, ALP, AST
Blood samples were planned to be collected to analyze the chemistry parameters: ALT, ALP and AST.
Time frame: Baseline (Day -1), and up to Day 38
Part B- Change From Baseline in Chemistry Parameter: Protein
Blood samples were planned to be collected to analyze the chemistry parameter: protein.
Time frame: Baseline (Day -1), and up to Day 38
Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA Arm
Urine samples were collected from participants for urinalysis for measuring potential of hydrogen (pH) and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells per high-power field (cells/HPF). Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.
Time frame: Baseline (Day -1) and at Day 17
Part A- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline: OCA + Linerixibat Arm
Urine samples were collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells/HPF. Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.
Time frame: Baseline (Day -1) and at Day 38
Part B- Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were planned to be collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was planned to be sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes.
Time frame: Baseline (Day -1), and up to Day 38
Part A- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.
Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Part A- Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) for Linerixibat: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.
Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Part A- Cmax for Linerixibat: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.
Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Part A- Tmax for Linerixibat: OCA + Linerixibat Arm
Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.
Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Part B- AUC(0-t) for Linerixibat: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.
Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Part B- AUC(0-12) for Linerixibat: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.
Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Part B- Cmax for Linerixibat: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.
Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Part B- Tmax for Linerixibat: OCA + Linerixibat Arm
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.
Time frame: Days 20 and 33: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
This was an open-label, drug interaction study to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and OCA conjugates in healthy participants. The study was conducted at a single center in the United Kingdom.
| Milestone | Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mg | Part B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg |
|---|---|---|
| Started | 19 | 0 |
| Completed | 19 | 0 |
| Not completed | 0 | 0 |
| Milestone | Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mg | Part B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg |
|---|---|---|
| Started | 19 | 0 |
| Completed | 18 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mg | Part B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg |
|---|---|---|
| Started | 0 | 0 |
| Completed | 0 | 0 |
| Not completed | 0 | 0 |
| Milestone | Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mg | Part B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg |
|---|---|---|
| Started | 0 | 0 |
| Completed | 0 | 0 |
| Not completed | 0 | 0 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Pharmacokinetic (PK) Parameters Population consisted of all participants for whom pharmacokinetic parameters were derivable.
| Hours*nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm | 2329.804 ± 43.54 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- AUC(0-t) for Total-OCA at Steady State: OCA + Linerixibat Arm | 782.528 ± 55.81 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Area Under the Concentration-time Curve From Time 0 to 24 Hour (AUC[0-24]) for Total-OCA at Steady State: OCA Arm | 2349.552 ± 43.55 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- AUC(0-24) for Total-OCA at Steady State: OCA + Linerixibat Arm | 787.007 ± 55.17 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Maximum Observed Concentration (Cmax) for Total-OCA at Steady State: OCA Arm | 206.409 ± 41.18 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Cmax for Total-OCA at Steady State: OCA + Linerixibat Arm | 83.403 ± 45.55 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.
| Nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Average Trough Concentration (Ctrough) for Total-OCA at Steady State: OCA Arm | 85.312 ± 53.13 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.
| Nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Average Ctrough for Total-OCA at Steady State: OCA + Linerixibat Arm | 21.680 ± 85.11 |
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours | Part A: OCA 10 mg |
|---|---|
| Part A- Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total-OCA: OCA Arm | 1.00 (0.3 to 5.0) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Tmax for Total-OCA: OCA + Linerixibat Arm | 3.00 (0.5 to 6.0) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Day 17 | 92.1116 ± 57.86113 |
| Day 18 | 95.1600 ± 57.50955 |
| Day 19 | 102.5168 ± 66.65649 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of total-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Day 35 | 30.8972 ± 25.55139 |
| Day 36 | 28.8489 ± 27.08479 |
| Day 37 | 26.4411 ± 21.63264 |
| Day 38 | 27.8644 ± 21.08848 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- AUC(0-t) for OCA: OCA Arm | 158.337 ± 59.45 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- AUC(0-t) for OCA: OCA + Linerixibat Arm | 127.171 ± 53.12 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- AUC(0-24) for OCA: OCA Arm | 163.701 ± 59.51 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours * nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- AUC(0-24) for OCA: OCA + Linerixibat Arm | 130.092 ± 53.80 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Cmax for OCA: OCA Arm | 50.820 ± 71.94 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Cmax for OCA: OCA + Linerixibat Arm | 35.495 ± 61.88 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.
| Nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Average Ctrough for OCA: OCA Arm | 2.609 ± 69.77 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.
| Nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Average Ctrough for OCA: OCA + Linerixibat Arm | 2.060 ± 83.57 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours | Part A: OCA 10 mg |
|---|---|
| Part A- Tmax for OCA: OCA Arm | 0.75 (0.3 to 11.0) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Tmax for OCA: OCA + Linerixibat Arm | 0.88 (0.5 to 12.0) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- AUC(0-t) for Tauro-OCA: OCA Arm | 712.567 ± 61.28 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- AUC(0-t) for Tauro-OCA: OCA + Linerixibat Arm | 89.486 ± 64.85 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- AUC(0-24) for Tauro-OCA: OCA Arm | 744.365 ± 68.92 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- AUC(0-24) for Tauro-OCA: OCA + Linerixibat Arm | 89.946 ± 64.50 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Cmax for Tauro-OCA: OCA Arm | 62.347 ± 60.84 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Cmax for Tauro-OCA: OCA + Linerixibat Arm | 10.224 ± 61.53 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.
| Nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Average Ctrough for Tauro-OCA: OCA Arm | 28.014 ± 76.45 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.
| Nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Average Ctrough for Tauro-OCA: OCA + Linerixibat Arm | 2.600 ± 124.06 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours | Part A: OCA 10 mg |
|---|---|
| Part A- Tmax for Tauro-OCA: OCA Arm | 2.00 (0.3 to 11.0) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of tauro-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Tmax for Tauro-OCA: OCA + Linerixibat Arm | 5.00 (2.0 to 9.0) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- AUC(0-t) for Glyco-OCA: OCA Arm | 1741.969 ± 44.11 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- AUC(0-t) for Glyco-OCA: OCA + Linerixibat Arm | 650.683 ± 58.17 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- AUC(0-24) for Glyco-OCA: OCA Arm | 1757.140 ± 44.10 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- AUC(0-24) for Glyco-OCA: OCA + Linerixibat Arm | 654.629 ± 57.45 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Cmax for Glyco-OCA: OCA Arm | 141.770 ± 39.46 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Cmax for Glyco-OCA: OCA + Linerixibat Arm | 65.633 ± 50.27 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 17, 18 and 19 has been presented.
| Nanogram per milliliter | Part A: OCA 10 mg |
|---|---|
| Part A- Average Ctrough for Glyco-OCA: OCA Arm | 66.043 ± 50.72 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis. Average of Ctrough measurement from study Days 35, 36, 37 and 38 has been presented.
| Nanogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Average Ctrough for Glyco-OCA: OCA + Linerixibat Arm | 19.498 ± 85.88 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours | Part A: OCA 10 mg |
|---|---|
| Part A- Tmax for Glyco-OCA: OCA Arm | 2.00 (0.3 to 5.0) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of glyco-OCA. Pharmacokinetic parameters were calculated using standard non-compartmental analysis.
| Hours | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Tmax for Glyco-OCA: OCA + Linerixibat Arm | 5.00 (1.0 to 6.0) |
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of total-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of tauro-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of glyco-OCA.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. All Participants Population consisted of all participants who took at least 1 dose of study intervention.
| Participants | Part A: OCA 10 mg | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|---|
| Any AEs | 10 | 14 |
| Any SAEs | 0 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement.
No measurements were reported for this outcome.
Twelve lead electrocardiograms (ECGs) were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millisecond | Part A: OCA 10 mg |
|---|---|
| PR Interval | -3.7 ± 8.27 |
| QRS Duration | -1.2 ± 4.66 |
| QT Interval | -3.4 ± 14.56 |
| QTcB Interval | 4.2 ± 13.31 |
| QTcF Interval | 1.6 ± 10.43 |
Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 5 minutes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millisecond | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| PR Interval | 2.5 ± 12.96 |
| QRS Duration | -2.3 ± 2.97 |
| QT Interval | -2.7 ± 13.05 |
| QTcB Interval | -2.9 ± 13.18 |
| QTcF Interval | -2.9 ± 9.58 |
Twelve lead ECGs were planned to be measured PR interval, QRS duration, QT interval, QTcB and QTcF. Twelve-lead ECGs were planned to be performed with the participant in a supine position after a rest of at least 5 minutes.
No measurements were reported for this outcome.
SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimeters of mercury | Part A: OCA 10 mg |
|---|---|
| SBP: Day 1 | -0.9 ± 6.83 |
| SBP: Day 17 | 0.5 ± 5.94 |
| DBP: Day 1 | -4.5 ± 4.17 |
| DBP: Day 17 | 0.1 ± 3.96 |
SBP and DBP were measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimeters of mercury | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| SBP | -0.7 ± 8.48 |
| DBP | 0.8 ± 2.98 |
Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Beats per minute | Part A: OCA 10 mg |
|---|---|
| Day 1 | 7.2 ± 6.54 |
| Day 17 | 1.8 ± 7.45 |
Pulse rate was measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Beats per minute | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Change From Baseline in Pulse Rate: OCA + Linerixibat Arm | -0.3 ± 8.96 |
Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Breaths per minute | Part A: OCA 10 mg |
|---|---|
| Day 1 | 0.2 ± 1.95 |
| Day 17 | 0.4 ± 1.77 |
Respiratory rate was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Breaths per minute | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Change From Baseline in Respiratory Rate: OCA + Linerixibat Arm | 0.4 ± 2.09 |
Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Degrees Celsius | Part A: OCA 10 mg |
|---|---|
| Day 1 | 0.15 ± 0.356 |
| Day 17 | 0.05 ± 0.336 |
Body temperature was measured in supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Degrees Celsius | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Change From Baseline in Body Temperature: OCA + Linerixibat Arm | 0.09 ± 0.327 |
SBP and DBP were planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.
No measurements were reported for this outcome.
Pulse rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.
No measurements were reported for this outcome.
Respiratory rate was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.
No measurements were reported for this outcome.
Body temperature was planned to be measured in a supine position after 5 minutes of rest for the participants in a quiet setting without distractions.
No measurements were reported for this outcome.
Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^9 cells per liter | Part A: OCA 10 mg |
|---|---|
| Basophils | -0.002 ± 0.0144 |
| Eosinophils | -0.013 ± 0.0549 |
| Lymphocytes | -0.091 ± 0.4444 |
| Monocytes | 0.033 ± 0.1125 |
| Neutrophils | 0.064 ± 0.8205 |
| Platelet count | 4.3 ± 22.85 |
| Leukocytes | -0.011 ± 0.7760 |
Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^9 cells per liter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Basophils | 0.000 ± 0.0091 |
| Eosinophils | 0.029 ± 0.0801 |
| Lymphocytes | 0.169 ± 0.3534 |
| Monocytes | 0.047 ± 0.0932 |
| Neutrophils | 0.278 ± 1.2073 |
| Platelet count | -4.1 ± 20.77 |
| Leukocytes | 0.524 ± 1.1981 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Part A: OCA 10 mg |
|---|---|
| Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA Arm | 0.4 ± 6.33 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Change From Baseline in Hematology Parameter: Hemoglobin: OCA + Linerixibat Arm | -0.8 ± 5.09 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Proportion of red blood cells in blood | Part A: OCA 10 mg |
|---|---|
| Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA Arm | -0.0003 ± 0.01614 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Proportion of red blood cells in blood | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Change From Baseline in Hematology Parameter: Hematocrit: OCA + Linerixibat Arm | -0.0054 ± 0.01857 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Picograms | Part A: OCA 10 mg |
|---|---|
| Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA Arm | -0.01 ± 0.624 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Picograms | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin: OCA + Linerixibat Arm | -0.13 ± 0.552 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Femtoliter | Part A: OCA 10 mg |
|---|---|
| Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA Arm | -0.37 ± 1.797 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Femtoliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume: OCA + Linerixibat Arm | -1.03 ± 1.972 |
Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^12 cells per liter | Part A: OCA 10 mg |
|---|---|
| Erythrocytes | 0.021 ± 0.1919 |
| Reticulocytes | -0.0004 ± 0.01165 |
Blood samples were collected to analyze the hematology parameters: erythrocytes and reticulocytes. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^12 cells per liter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Erythrocytes | 0.002 ± 0.2340 |
| Reticulocytes | 0.0074 ± 0.01650 |
Blood samples were planned to be collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet count and leukocytes.
No measurements were reported for this outcome.
Blood samples were planned to be collected to analyze the hematology parameter: hemoglobin.
No measurements were reported for this outcome.
Blood samples were planned to be collected to analyze the hematology parameter: hematocrit.
No measurements were reported for this outcome.
Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.
No measurements were reported for this outcome.
Blood samples were planned to be collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.
No measurements were reported for this outcome.
Blood samples were planned to be collected to analyze the hematology parameters: erythrocytes and reticulocytes.
No measurements were reported for this outcome.
Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimoles per liter | Part A: OCA 10 mg |
|---|---|
| Glucose | -0.09 ± 0.537 |
| Calcium | 0.041 ± 0.0891 |
| Potassium | -0.02 ± 0.429 |
| Sodium | -0.2 ± 2.10 |
| Urea | -0.0395 ± 0.32717 |
Blood samples were collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimoles per liter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Glucose, n=18 | -0.44 ± 0.343 |
| Calcium, n=18 | -0.001 ± 0.0506 |
| Potassium, n=16 | 0.10 ± 0.493 |
| Sodium, n=18 | -0.9 ± 1.89 |
| Urea, n=18 | -0.1507 ± 0.24902 |
Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Micromoles per liter | Part A: OCA 10 mg |
|---|---|
| Bilirubin | 0.1 ± 2.42 |
| Creatinine | -2.2 ± 7.71 |
| Direct Bilirubin | 0.0001 ± 0.88192 |
Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Micromoles per liter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Bilirubin, n=18 | 1.1 ± 2.72 |
| Creatinine, n=18 | 5.4 ± 6.83 |
| Direct Bilirubin, n=16 | 0.3126 ± 0.79317 |
Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| International units per liter | Part A: OCA 10 mg |
|---|---|
| ALT | -2.7 ± 4.75 |
| ALP | 0.6 ± 5.50 |
| AST | -2.2 ± 3.03 |
Blood samples were collected to analyze the chemistry parameters: ALT, ALP and AST. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| International units per liter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| ALT, n=17 | 9.4 ± 38.04 |
| ALP, n=18 | 0.0 ± 9.49 |
| AST, n=16 | -0.9 ± 8.50 |
Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Part A: OCA 10 mg |
|---|---|
| Part A- Change From Baseline in Chemistry Parameter: Protein: OCA Arm | 1.5 ± 3.13 |
Blood samples were collected to analyze the chemistry parameter: protein. Baseline was considered as Day -1. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Part A- Change From Baseline in Chemistry Parameter: Protein: OCA + Linerixibat Arm | 0.7 ± 2.66 |
Blood samples were planned to be collected to analyze the chemistry parameters: glucose, calcium, potassium, sodium and urea.
No measurements were reported for this outcome.
Blood samples were planned to be collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin.
No measurements were reported for this outcome.
Blood samples were planned to be collected to analyze the chemistry parameters: ALT, ALP and AST.
No measurements were reported for this outcome.
Blood samples were planned to be collected to analyze the chemistry parameter: protein.
No measurements were reported for this outcome.
Urine samples were collected from participants for urinalysis for measuring potential of hydrogen (pH) and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells per high-power field (cells/HPF). Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.
| Participants | Part A: OCA 10 mg |
|---|---|
| Cellular casts: No change | 5 |
| Cellular casts: Increase to 1-9/HPF | 0 |
| Erythrocytes: No change | 4 |
| Erythrocytes: Increase to 1-9/HPF | 1 |
| Granular casts: No change | 5 |
| Granular casts: Increase to 1-9/HPF | 0 |
| Hyaline casts: No change | 5 |
| Hyaline casts: Increase to 1-9/HPF | 0 |
| Leukocytes: No change | 4 |
| Leukocytes: Increase to 1-9/HPF | 1 |
Urine samples were collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes and were counted as cells/HPF. Baseline was considered as Day -1. Number of participants with worst case urinalysis result by microscopic examination have been presented.
| Participants | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Cellular casts: No change | 1 |
| Cellular casts: Increase to 1-9/HPF | 0 |
| Erythrocytes: No change | 0 |
| Erythrocytes: Increase to 1-9/HPF | 1 |
| Granular casts: No change | 1 |
| Granular casts: Increase to 1-9/HPF | 0 |
| Hyaline casts: No change | 1 |
| Hyaline casts: Increase to 1-9/HPF | 0 |
| Leukocytes: No change | 1 |
| Leukocytes: Increase to 1-9/HPF | 0 |
Urine samples were planned to be collected from participants for urinalysis for measuring pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Abnormal urinalysis was planned to be sent for microscopic examination for cellular casts, erythrocytes, granular casts, hyaline casts, and leukocytes.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.
| Hours*picogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Day 20, n=16 | 230.609 ± 153.14 |
| Day 33, n=19 | 903.881 ± 142.27 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.
| Hours*picogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Day 20, n=13 | 322.580 ± 121.05 |
| Day 33, n=17 | 1071.982 ± 144.57 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.
| Picogram per milliliter | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Day 20, n=17 | 56.927 ± 173.55 |
| Day 33, n=19 | 163.624 ± 123.48 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of linerixibat. Pharmacokinetic parameters were analyzed using standard non-compartmental methods.
| Hours | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|
| Day 20, n=17 | 3.92 (0.3 to 8.0) |
| Day 33, n=19 | 5.00 (0.5 to 9.0) |
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of linerixibat.
No measurements were reported for this outcome.
Collected over AEs and SAEs were collected up to Day 52 in Part A. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: OCA 10 mg | 0/19 (0%) | 0/19 (0%) | 10/19 (52.6%) |
| Part A: OCA 10 mg + Linerixibat 90 mg | 0/19 (0%) | 1/19 (5.3%) | 14/19 (73.7%) |
| Event | Part A: OCA 10 mg | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|---|
| Deep vein thrombosisVascular disorders | 0/19 | 1/19 |
| Event | Part A: OCA 10 mg | Part A: OCA 10 mg + Linerixibat 90 mg |
|---|---|---|
| Abdominal discomfortGastrointestinal disorders | 0/19 | 5/19 |
| DiarrhoeaGastrointestinal disorders | 0/19 | 4/19 |
| HeadacheNervous system disorders | 4/19 | 1/19 |
| NasopharyngitisInfections and infestations | 3/19 | 0/19 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 2/19 | 1/19 |
| RashSkin and subcutaneous tissue disorders | 1/19 | 2/19 |
| Transaminases increasedInvestigations | 0/19 | 2/19 |
| Decreased appetiteMetabolism and nutrition disorders | 1/19 | 2/19 |
| Abdominal painGastrointestinal disorders | 1/19 | 1/19 |
| Abdominal pain upperGastrointestinal disorders | 1/19 | 0/19 |
The study was concluded after complete analysis of Part A, there was no clinical benefit seen in conducting Part B of this study, no participants were enrolled in Part B.
| Age, Continuous(Years) | Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mg | Part B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg | Total |
|---|---|---|---|
| Mean | 44.9 ± 10.28 | — | 44.9 ± 10.28 |
| Sex: Female, Male(Participants) | Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mg | Part B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg | Total |
|---|---|---|---|
| Female | 1 | — | 1 |
| Male | 18 | — | 18 |
| Race/Ethnicity, Customized(Participants) | Part A: OCA 10 mg Followed by OCA 10 mg + Linerixibat 90 mg | Part B: OCA 5mg or 10mg Followed by OCA 10mg+Linerixibat 180mg | Total |
|---|---|---|---|
| Black or African American | 1 | — | 1 |
| White - White/Caucasian/European Heritage | 18 | — | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a data sharing agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Aug 2019 to primary completion in Nov 2019, 2 months.
Results were first posted in Jul 2020, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Linerixibat · Obeticholic acid